Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia.

[1]  D. C. Hurst,et al.  Niacin revisited: clinical observations on an important but underutilized drug. , 1991, The American journal of medicine.

[2]  E. Moriguchi,et al.  Effects of probucol on plasma lipoprotein subfractions and activities of lipoprotein lipase and hepatic triglyceride lipase. , 1991, Atherosclerosis.

[3]  E. Muls,et al.  The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia , 1990, Journal of internal medicine.

[4]  S. Grundy.  Cholesterol and Atherosclerosis: Diagnosis and Treatment , 1990 .

[5]  P. Reaven,et al.  Lovastatin, nicotinic acid, and rhabdomyolysis. , 1988, Annals of internal medicine.

[6]  L T Chylack,et al.  Lens Opacities Classification System. , 1988, Archives of ophthalmology.

[7]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[8]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[9]  B. Angelin,et al.  Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. , 1993, The American journal of medicine.

[10]  T. Miller,et al.  Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. , 1991, Mayo Clinic proceedings.